Author name: info@sophiaadesigns.com

Activating T cells to fight cancer

Marengo Therapeutics’ breakthrough discovery in T cell receptor (TCR) activation blazes a new trail for safe treatment and long-term protection against cancer. Immuno-oncology (IO) has transformed cancer care to significantly benefit patients with both blood and solid-tumor malignancies. Despite recent advances, two-thirds of patients do not achieve durable responses to current therapies, which has been …

Activating T cells to fight cancer Read More »

Ipsen, continuing oncology push, pays a startup $45M for two cancer drugs

Aiming to bolster a yearslong effort to build up an oncology business, French drugmaker Ipsen announced Monday a deal with startup Marengo Therapeutics to co-develop two potential cancer medicines. Marengo is relatively new, having launched last November with $80 million from life sciences venture firm ATP to develop cancer immunotherapies. The startup is working on antibody drugs that bind …

Ipsen, continuing oncology push, pays a startup $45M for two cancer drugs Read More »

Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer

Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. The Paris-based company is collaborating with Marengo Therapeutics on the development of two drugs that selectively activate T cells to fight cancer. On the heels of reaching an acquisition agreement …

Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer Read More »